These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30191846)

  • 81. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
    Katsios C; Ziogas DE; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
    [No Abstract]   [Full Text] [Related]  

  • 82. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?
    Goldberg RM
    Oncologist; 2015 Dec; 20(12):1448-56. PubMed ID: 26512044
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.
    Sternberg CN; Beltran H
    Nat Rev Urol; 2017 Feb; 14(2):71-72. PubMed ID: 28050016
    [No Abstract]   [Full Text] [Related]  

  • 84. Patient-centric trials for therapeutic development in precision oncology.
    Biankin AV; Piantadosi S; Hollingsworth SJ
    Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?
    Freidlin B; Allegra CJ; Korn EL
    J Natl Cancer Inst; 2020 Aug; 112(8):773-778. PubMed ID: 31868907
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
    Galanis E; Wu W; Sarkaria J; Chang SM; Colman H; Sargent D; Reardon DA
    Curr Oncol Rep; 2011 Feb; 13(1):42-9. PubMed ID: 21125354
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine.
    Dickson D; Johnson J; Bergan R; Owens R; Subbiah V; Kurzrock R
    Cell; 2020 Jan; 180(1):9-14. PubMed ID: 31951522
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Biomarker-guided therapy for colorectal cancer: strength in complexity.
    Sveen A; Kopetz S; Lothe RA
    Nat Rev Clin Oncol; 2020 Jan; 17(1):11-32. PubMed ID: 31289352
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical trials: More trials, fewer tribulations.
    Eisenstein M
    Nature; 2014 May; 509(7502):S55-7. PubMed ID: 24870821
    [No Abstract]   [Full Text] [Related]  

  • 90. Targeted therapies: What have we learned from SHIVA?
    Le Tourneau C; Kurzrock R
    Nat Rev Clin Oncol; 2016 Dec; 13(12):719-720. PubMed ID: 27725677
    [No Abstract]   [Full Text] [Related]  

  • 91. A conditional error function approach for subgroup selection in adaptive clinical trials.
    Friede T; Parsons N; Stallard N
    Stat Med; 2012 Dec; 31(30):4309-20. PubMed ID: 22865774
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.
    Berry DA; Herbst RS; Rubin EH
    Clin Cancer Res; 2012 Feb; 18(3):638-44. PubMed ID: 22298897
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.
    Arai RJ; Guindalini RSC; Llera AS; O'Connor JM; Muller B; Lema M; Freitas HC; Soria T; Delgado L; Landaverde D; Montenegro P; Riechelmann RP
    Oncologist; 2019 Aug; 24(8):e709-e719. PubMed ID: 30910864
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
    Shih WJ; Lin Y
    Stat Med; 2018 Feb; 37(5):687-709. PubMed ID: 29205435
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Overcoming implementation challenges of personalized cancer therapy.
    Meric-Bernstam F; Mills GB
    Nat Rev Clin Oncol; 2012 Sep; 9(9):542-8. PubMed ID: 22850751
    [TBL] [Abstract][Full Text] [Related]  

  • 96. TRIUMPH Trial: One Small Step Could Become One Giant Leap for Precision Oncology in Head and Neck Cancer.
    Keam B; Kim HR; Yun HJ
    Cancer Res Treat; 2019 Jan; 51(1):413-414. PubMed ID: 30064199
    [No Abstract]   [Full Text] [Related]  

  • 97. Fear of Cancer Recurrence in an Era of Personalized Medicine.
    Thewes B; Husson O; Poort H; Custers JAE; Butow PN; McLachlan SA; Prins JB
    J Clin Oncol; 2017 Oct; 35(29):3275-3278. PubMed ID: 28723231
    [No Abstract]   [Full Text] [Related]  

  • 98. Precision medicine and the rapidly approaching future of cancer management.
    Markman M
    Am J Manag Care; 2012 Dec; 18(5 Spec No.):SP207-8, cover. PubMed ID: 23301708
    [No Abstract]   [Full Text] [Related]  

  • 99. Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.
    Schuck RN; Woodcock J; Zineh I; Stein P; Jarow J; Temple R; Permutt T; LaVange L; Beaver JA; Charlab R; Blumenthal GM; Dorff SE; Leptak C; Lemery S; Rogers H; Chowdhury B; Litwack ED; Pacanowski M
    Clin Pharmacol Ther; 2018 Aug; 104(2):282-289. PubMed ID: 29473145
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.
    Riess JW; Rolfo C; Gandara DR
    Clin Lung Cancer; 2021 May; 22(3):153-155. PubMed ID: 33879399
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.